FDA Clearance Tracker · P960007-S014
TRANSCYTE(TM)
Last checked: Nov 20, 2026Latest source record: May 19, 2000 (this decision)Source: openFDAMethods & limitations
Decided
May 19, 2000
Approved
Time to decision
79 days
Received Mar 1, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P960007-S014
- Device name
- TRANSCYTE(TM)
- Applicant
- Shire Regenerative Medicine
- Applicant location
- San Diego, CA
- Received
- Mar 1, 2000
- Decided
- May 19, 2000
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P960007
Device type
- Device type
- Dressing, wound and burn, interactive (MGR)
- Device class
- Class III
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL TO CONDUCT THE FINAL PRODUCT STERILITY TEST IN-HOUSE UNDER THE CONDITIONS OF AN ISOLATOR ENVIRONMENT.
Source documents
Other decisions for Shire Regenerative Medicine
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.